Protocolli GOIRC-sponsored in fase di discussione

GOIRC-01-2024  PRELUDE

Pembrolizumab plus lenvatinib in REcurrent ccRCC patients failing permbroLizUmab aDjuvant treatment - PRELUDE Trial

Centro Coordinatore: Terni

GOIRC-04-2024 CECYDE

A multicenter open-label phase II study of Cemiplimab plus chemotherapy, selected on the basis of baseline cytidine deaminase activity, in advanced squamous non-small cell lung cancer - CECYDE trial

Centro Coordinatore: Lucca

GOIRC-05-2024 PREMAR (osservazionale)

PREvalence and PREdictive role of bioMARkers in advanced/metastatic gastric or gastroesophageal junction cancer patients: A multicenter prospective Observational Study – PREMAR

Centro Coordinatore: Reggio Emilia

GOIRC-07-2024 RESCUE

A multicenter, open-label, randomized phase III trial investigating the efficacy of Cemiplimab combined with histology-driven chemotherapy as a salvage treatment for patients with advanced non-small cell lung cancer (NSCLC) with PD-L1 ≥50% showing primary resistance to first-line immunotherapy

Centro Coordinatore: Bologna